Anavex Life Sciences Corp (AVXL)

[polarbear77]

Right on jimmy667, I completely agree and I give further credit to Georgejii for his recent post:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151171967

Wherein George outlines the common MOA/biomarker targets between BOTH Rett Syndrome and PD (as well as Fibromyalgia and Chronic Fatigue Syndrome).

And you mentioned potential commonality for Fragile X, Infantile Spasms and Angelman's as well.

Seems to be either an A-HA or an OH-SH$T moment, depending on what side you’re on.

As georgejii summarized in his post: “So ideally, we want glutamate to decrease and GABA to increase as a result of treatment with Anavex 2-73 and/or Anavex 3-71.”

And our CMO on 9/16/19 reported that plasma levels of the biomarker Glutamate decreased significantly in our preliminary results of our 6 Rett Syndrome participants, and these levels were directly correlated with CGI-I scores at Week 7.

Additionally, “the magnitude of GABA change was inversely correlated with the magnitude of decrease in RSBQ Total scores”. And “GABA is the main inhibitory neurotransmitter in the brain, known to be deficient in animal models of Rett syndrome.”

Also georgejii provided the excerpted article quote “Parkinson's disease is a neurodegenerative disease with motor and non-motor symptoms. In Parkinson's disease, a neurotransmitter imbalance occurs in the extrapyramidal system with a dopamine and GABA deficiency and an acetylcholine and glutamate surplus.”
So the same biomarker/objectives in Rett Syndrome and PD to increase GABA and decrease glutamate.

And this is what our CMO Dr Walter Kaufmann told us on 9/16 has occurred thus far on a LOW 5mg daily oral liquid dose of 2-73 over just 7 weeks in our first Rett Syndrome participants, and that he plans to provide detailed analysis in Finland on Friday.

I’m no scientist but seemingly these Anavex 2-73 benefits would translate and provide therapeutic benefits across these multiple indications with the common goals of increasing GABA and decreasing glutamate.

I’d expect that this 6 patient result and its MOA commonality across (at least 4-7) indications likely is one of Anavex’s upcoming topics of conversation with the FDA and EMA.

If Drs Kaufmann and Missling have additional confirmatory data to provide regulators in their upcoming meetings, then in my opinion, there should be serious consideration given to either accelerated approval or breakthrough designation.